302例他汀类药物相关肌肉系统损害的文献分析

摘要
图/表
参考文献(54)
相关文章 (15)

全文: PDF (737 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS)

摘要目的研究他汀类药物相关肌肉系统损害在中国人群中的规律和特点,为临床合理用药提供参考。方法以“他汀”、“肌病”为关键词,检索中国知网全文数据库,根据纳入、排除标准对文献进行数据提取和分析。结果共纳入34篇文献,302例病例。辛伐他汀病例最多。共涉及8类严重药物相互作用。结论应合理选用他汀类药物,警惕药物相互作用并做好相关肌肉系统损害的处理和预防。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	高千秋
	张浩嘉

关键词 ：他汀类药物相关肌肉系统损害, 药物相互作用, 文献分析

Abstract：Objective To provide references for rational medication through analyzing the characteristics of statin-induced muscular system disorders. Methods "Statin" and "myopathy" were used as keywords to search articles in CNKI database, then they were analyzed according to inclusion and exclusion criteria. Results A total of 34 articles were included, involving 302 cases. Simvastatin was the most common drug reported with myopathy. Eight kinds of drug-drug interaction were found. Conclusion It is important to choose proper statin and monitor drug interaction. More attention should be paid to treatment and prophylaxis of statin-induced muscular system disorders.

Key words： statin-induced musculer system disorders drug interaction literature analysis

收稿日期: 2018-10-11

PACS:

R994.11

作者简介: 高千秋,女,本科,副主任药师,临床药学。

引用本文:

高千秋, 张浩嘉. 302例他汀类药物相关肌肉系统损害的文献分析[J]. 中国药物警戒, 2018, 15(8): 476-480.
GAO Qianqiu, ZHANG Haojia. Literature Analysis of 302 Cases of Musuler System Disorders Induced by Statins. Chinese Journal of Pharmacovigilance, 2018, 15(8): 476-480.

链接本文:

http://www.zgywjj.com/CN/ 或 http://www.zgywjj.com/CN/Y2018/V15/I8/476

[1] 诸骏仁, 高润霖, 赵水平,等. 中国成人血脂异常防治指南(2016年修订版)[J]. 中国循环杂志, 2016, 16(10):15-35.
[2] Kim K, Johnson J A, Derendorf H.Differences in Drug Pharmacokinetics Between East Asians and Caucasians and the Role of Genetic Polymorphisms[J]. Journal of Clinical Pharmacology, 2013, 44(10):1083-1105.
[3] Liao J K.Safety and efficacy of statins in Asians[J]. American Journal of Cardiology, 2007, 99(3):410-414.
[4] 王佩, 刘恩生, 李玉珍. 辛伐他丁致药物性肌病[J]. 药物不良反应杂志, 1999, 1(1):50-51.
[5] 陈培莉, 赵全明, 徐予,等. 西立伐他汀、吉非贝齐合用引起严重横纹肌溶解症[J]. 药物不良反应杂志, 2001, 3(3):162-164.
[6] 李茂亭, 马娜. 辛伐他丁肌病二例报告[J]. 实用心脑肺血管病杂志, 2001, 9(2):90.
[7] 罗颂武. 舒降之引起肌病一例[J]. 今日药学, 2002, 12(4):49.
[8] 梅琪, 杨鲁渤, 范仰刚. 辛伐他汀致药源性肌病[J]. 药物不良反应杂志, 2003, 5(2):87.
[9] 黄立, 李红, 潘纬. 辛伐他汀与烟酸联用致严重肌病2例[J]. 川北医学院学报, 2004, 19(4):250-251.
[10] 李欣, 高鑫. 他汀类药物引起的肌病一例[J]. 中华全科医师杂志, 2004, 3(1):43-44.
[11] 李正业, 黄嵩, 曾波. 辛伐他汀与口服红霉素配伍致严重肌病8例[J]. 四川医学, 2004, 25(3):323.
[12] 魏子秀, 孙晓斐. 氟伐他汀与华法林合用导致肌病一例[J]. 中国循环杂志, 2004, 19(4):269.
[13] 周少丹, 汪瑜章. 阿托伐他汀(立普妥)致肌病一例[J]. 中国药师, 2005, 8(3):234-235.
[14] 刘晓凯. 辛伐他汀致肌病及急性肾功能不全一例报告[J]. 浙江临床医学, 2006, 8(1):85.
[15] 彭婕, 葛兆霞, 王颖捷. 口服辛伐他汀致肌病1例[J]. 药物流行病学杂志, 2007, 16(5):314.
[16] 苏前. 他汀类药物致肌病(附5例分析)[J]. 临床神经病学杂志, 2007, 20(4):58-59.
[17] 王宁, 陈海平. 他汀类药物致肌病的临床调查与分析[J]. 药物不良反应杂志, 2007, 9(6):384-387.
[18] 杨金彪. 口服辛伐他汀致肌病1例[J]. 中国药师, 2008, 11(1):85.
[19] 张松村, 刘辉. 辛伐他汀致多发肌炎1例报告[J]. 内蒙古中医药, 2008(4):39.
[20] 朱晓玲, 王素征. 阿托伐他汀致肌病1例[J]. 人民军医, 2008, 51(1):23.
[21] 韩毛毛, 应月华, 林小娟. 他汀类药物引起相关肌病2例的护理[J]. 护理与康复, 2010, 09(8):720-721.
[22] 唐浩军. 洛伐他汀致药物性肌病2例分析[J]. 内蒙古中医药, 2010, 29(8):46.
[23] 丁荣晶, 马丽. 辛伐他汀合用帕罗西汀致急性肝损害及肌病1例[J]. 中国新药杂志, 2011(15):1476-1477.
[24] 刘峰, 刘锐锋. 辛伐他汀致肝功能异常和肌病1例[J]. 中国药物警戒, 2012, 9(6):379.
[25] 李小玉, 张赟, 刘玉兰. 普伐他汀致老年患者横纹肌溶解症[J]. 药物不良反应杂志, 2012, 14(4):263-266.
[26] 王斌, 刘桂花. 辛伐他汀导致肝损害和肌病1例[J]. 中国临床药理学杂志, 2012, 28(1):62-63.
[27] 徐鹏, 张国柱. 他汀类药物相关性肌病及肝损害的药学监护[J]. 安徽医药, 2013, 17(1):150-151.
[28] 游俊丽, 范书英. 他汀性肌病两例并文献复习[J]. 中国全科医学, 2013, 16(2):221-224.
[29] 李艺, 张亚同. 临床药师参与1例普伐他汀致肌炎的药学实践[J]. 临床药物治疗杂志, 2014, 12(4):54-56.
[30] 马伟伟. 辛伐他汀致横纹肌溶解症1例并文献复习[J]. 实用医药杂志, 2014, 31(11):996-998.
[31] 肖滨. 他汀类药物治疗后疑似引起肌病1例[J]. 中国乡村医药, 2014, 21(19):48-49.
[32] 修双玲, 王立, 贾克宝,等. 糖尿病患者应用他汀药物致肌病8例报告[J]. 山西医科大学学报, 2014, 45(12):1183-1186.
[33] 赵玉芬, 王燕芬, 周淑玲. 阿托伐他汀钙片口服致肌酶升高2例[J]. 中国药业, 2014, 23(12):112.
[34] 朱明成. 他汀类药物引起相关性肌病不良反应的调查分析[J]. 中国当代医药, 2015, 22(26):180-182.
[35] 邹钒, 郑天衡, 朱鑫璞. 他汀类药物相关肌病(肌炎)1例报告[C]. 中华医学会第十八次全国神经病学学术会议论文汇编, 2015, 723.
[36] 程丽丹, 江一唱. 196例肌酸激酶异常升高病例分析[J]. 临床急诊杂志, 2016, 17(4):304-307.
[37] 江岳鑫, 娄莹, 刘玉清,等. 他汀类药物致160例肌病相关不良反应的临床分析[J]. 中华高血压杂志, 2015, 42(6):905-909.
[38] IBM Micromedex. Drug interaction[DB/OL].[2018-01-08]. http://
www.micromedexsolutions.com/micromedex2/librarian/PFDef-
39 aultActionId/evidencexpert.ShowDrugInteractionsResults.
[39] Group H C, Haynes R, Jiang L, et al.Fast Track: Editor's choice: HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-
risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes,reasons for stopping study treatment[J]. European Heart Journal, 2013, 34(17):1279-1291.
[40] Rosenson R S, Baker S K, Jacobson T A, et al.An assessment by the Statin Muscle Safety Task Force: 2014 update[J]. Journal of Clinical Lipidology, 2014, 8(3):S58-S71.
[41] Graham D J, Staffa J D, Andrade S E, et al.Incidence of hospitalized rhabdomyolysis in patients treated with lipid-lowering drugs[J]. Jama the Journal of the American Medical Association, 2004, 292(21):2585-2590.
[42] Bruckert E, Hayem G, Dejager S, et al.Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study[J]. Cardiovasc Drugs Ther, 2005, 19(6):403-414.
[43] Pfeffer M A, Keech A, Sacks F M, et al.Safety and tolerability of pravastatin in long-term clinical trials: prospective Pravastatin Pooling (PPP) Project[J]. Circulation, 2002, 105(20):2341-2346.
[44] Ridker P M, Danielson E, Fonseca FA, et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein[J]. Current Atherosclerosis Reports, 2008, 11(4):243-244.
[45] Al-Jubouri M A, Briston P G, Sinclair D, et al. Myxoedema revealed by simvastatin induced myopathy[J]. Bmj, 1994, 308(6928):588.
[46] Scalvini T, Marocolo D, Cerudelli B, et al.Pravastatin-associated myopathy. Report of a case[J]. Recenti Progressi in Medicina, 1995, 86(5):198.
[47] Vladutiu G D.Genetic predisposition to statin myopathy[J]. Current Opinion in Rheumatology, 2008, 20(6):648.
[48] Mancini G B J, Tashakkor A Y, Baker S, et al. Diagnosis, prevention, and management of statin adverse effects and intolerance: Canadian Working Group Consensus update[J]. Canadian Journal of Cardiology, 2016, 32(7):S35-S65.
[49] Patel A M, Shariff S, Bailey D G, et al.Statin Toxicity From Macrolide Antibiotic Coprescription: A Population-Based Cohort Study[J]. Annals of Internal Medicine, 2014, 46(1):156.
[50] Kashani A, Phillips C O, Foody J M, et al.Risks associated with statin therapy: a systematic overview of randomized clinical trials[J]. Circulation, 2006, 114(25):2788-2797.
[51] Melli G, Chaudhry V, Cornblath D R.Rhabdomyolysis: an evaluation of 475 hospitalized patients[J]. Medicine, 2005, 84(6):377.
[52] Robert S R, Steven K B. Statin muscle-related adverse events[DB/OL].(2017-09-22) [2018-02-07]. https://www.uptodate.com/
contents/statin-muscle-related-adverse-events.
[53] Alshekhlee A, Katirji B, Alshekhlee A, et al.Clinical perspectives of statin-induced rhabdomyolysis[J]. American Journal of Medicine, 2007, 120(12):400-409.
[54] Rosenson R S.Current overview of statin-induced myopathy[J]. American Journal of Medicine, 2004, 116(6):408-416.